Search Results
Jan 15, 2026, 09:05 ET Parloa Valued at $3 Billion with $350M Series D to Lead Agentic AI for Customer Experience
in a crowded market."Apoorv Agrawal, Partner at Altimeter Capital: "Parloa combines a leading agentic AI platform with the enterprise DNA to deploy it at scale - forward-deployed engineers on the ground, Fortune 500 customers in production, and a world-class go-to-market team armed with
More news about: Parloa
Jan 15, 2026, 08:58 ET BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare
The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit
More news about: BillionToOne
Jan 15, 2026, 08:30 ET Mito Red Light Introduces MitoGLOW™ - A New Standard in Facial & Neck Light Therapy Design
around the world. The company specializes exclusively in light-based technology – not cosmetics or beauty accessories – and brought that same engineering DNA to the development of MitoGLOW."MitoGLOW is a natural extension of what we've been building for years," said Scott Chaverri, Founder & CEO
More news about: Mito Red Light
Jan 15, 2026, 07:00 ET BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence
"Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus
More news about: Blood Profiling Atlas in Cancer (BLOODPAC) Consortium
Jan 15, 2026, 07:00 ET BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence
"Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus
More news about: Blood Profiling Atlas in Cancer (BLOODPAC) Consortium
Jan 15, 2026, 00:01 ET ATLAS OCEAN VOYAGES UNVEILS ELEVATED BRAND IDENTITY, REINFORCING ITS POSITION AS A LEADER IN YEAR-ROUND LUXURY EXPEDITION CRUISING
emphasizes connection, discovery, and the boutique hospitality mindset, aligning marketing and communication across all platforms.Brand DNA: The brand emphasizes Intimacy, Hospitality, Passion, Immersion, Conscious Design, and Community, highlighting the tangible and emotional aspects of
More news about: Atlas Ocean Voyages
Jan 14, 2026, 08:00 ET From Path to Progress: Journal of Independent Medicine Launches 2026 With Its Fifth Issue--Entering Year Two of Conflict-Free, Evidence-Based Science
Hybrids Survive Digestion in mRNA Vaccine Manufacturing — Kevin McKernan; Charles Rixey; Jessica RoseFinds evidence of residual DNA-related impurities—particularly RNA:DNA hybrids—in tested mRNA vaccine lots and argues current dsDNA-only quantification approaches may underestimate
More news about: Independent Medical Alliance
Jan 14, 2026, 03:22 ET Valmet will support Faderco Group doubling tissue production capacity with a third Advantage DCT tissue line
Valmet DNA Automation System with process and machine controls. Complete mill engineering, installation supervision, training, start-up and commissioning are
More news about: Valmet Oyj
Jan 14, 2026, 01:10 ET 2026 DotAI 年度大會圓滿舉行
「Advoo」。針對營銷人員需在多個工具間切換的痛點（例如：ChatGPT 寫文案、Midjourney 出圖、Canva 排版），Advoo 提供了一站式的解決方案。Advoo 能根據用戶輸入的場景，自動分析賣點、定義品牌語氣、搜尋素材，並生成符合品牌 DNA 的高品質社群帖文與產品海報。更重要的是，它具備「記憶能力」，能隨著用戶的使用不斷學習其審美偏好，建立專屬的品牌資產庫。Advoo 現正開放 Beta 版招募測試，邀請全港營銷人員率先體驗「從意念到發佈」的秒速工作流。全員賦能：獨家發佈《2026 實戰電子書》及 AI 路線圖「未來的競爭，不是人與
More news about: DotAI
Jan 13, 2026, 12:31 ET Revizto launches renewed brand and mission focus for next phase of growth
earlier and support more confident decision-making throughout the lifecycle of a program.Arman Gukasyan, Founder and CEO of Revizto, said: "Our DNA hasn't changed. We're still focused on helping people work together better and avoid unnecessary friction. What has changed is the reality of today's
More news about: Revizto
Jan 13, 2026, 12:00 ET U.S.-Premiere Headline Exhibit Doctor Who Worlds of Wonder: Where Science Meets Fiction Extended at Comic-Con Museum
and earth sciences, taking them on a journey from the furthest stars to the depths of the ocean."Science has been part of Doctor Who's DNA since the first episode aired in 1963," said Steven Swaby, Doctor Who Worlds of Wonder exhibition curator. "Connecting the threads that inspired
More news about: Comic-Con Museum
Jan 13, 2026, 12:00 ET Wintermute's OTC Markets 2025 report shows crypto's upper tier becoming an established asset class as liquidity concentrates
This reach now extends further into traditional finance, with active trading on exchanges such as CME and Eurex. Building is central to Wintermute's DNA, with the company incubating new protocols, some of which have grown into independent businesses.Media ContactM Group Strategic
More news about: Wintermute
Jan 13, 2026, 09:30 ET The Mark Foundation for Cancer Research Announces 2026 Emerging Leader Awards, Committing $3.75 Million to Next-Generation Oncology Breakthroughs
Molecular Mechanisms of DNA Replication and Epigenetic InheritanceUtilizing "visual biochemistry" at atomic resolution to identify how errors in DNA replication drive cancer, revealing new targets for drug development.Mariella
More news about: The Mark Foundation for Cancer Research
Jan 13, 2026, 09:15 ET Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jan 13, 2026, 09:09 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they
More news about: EspeRare Foundation
Jan 13, 2026, 09:00 ET Juniper Square Integrates Nasdaq eVestment™ to Advance Transparency and Institutional Access for Private Markets IR Teams
unified across platforms, eliminating the need to manually reconcile LP and consultant names."Innovation for IR teams has been part of our DNA since day one," said Jay Farber, GM of GPX, Juniper Square. "By connecting our AI CRM to Nasdaq eVestment, we're enabling always-on intelligence
More news about: Juniper Square
Jan 13, 2026, 09:00 ET A NEW ERA OF VALUE: TACO BELL® LAUNCHES THE NEW LUXE VALUE MENU FEATURING TEN CRAVEABLE ITEMS ALL $3 OR LESS
can't make it to the event can still create their own lap of luxury — whether in the drive-thru or from the comfort of home.Value Is in Our DNAFrom the legendary Cravings Value Menu to the wildly popular Luxe Boxes, Taco Bell has long defined what value looks like. But in 2026,
More news about: Taco Bell Corp.
Jan 13, 2026, 09:00 ET Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jan 13, 2026, 08:45 ET MySize Explores Unlocking the "DNA of Fashion" Through Privacy-First Data Intelligence
content:https://www.prnewswire.com/news-releases/mysize-explores-unlocking-the-dna-of-fashion-through-privacy-first-data-intelligence-302659552.htmlSOURCE
More news about: My Size Inc.
Jan 13, 2026, 08:38 ET NOW® Survey Uncovers The Wellness And Health Priorities Shaping Consumers' Supplement Use In 2026
probiotic (NOW is one of the only supplement companies to test for exact DNA strains via their RiboPrinter technology).Additional Wellness Priorities and Supplements to Consider:Immune Health*:
More news about: NOW®
Jan 13, 2026, 08:00 ET Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026
More news about: Ginkgo Bioworks
Jan 13, 2026, 07:07 ET Leo International Group Relocates Global Headquarters to Singapore Ahead of Its Centennial
American corporations that had survived wars, industrial shifts, technological disruption and changing consumer values, my experience taught me this: the DNA of a century-old enterprise must be etched with discipline and altruism because if those remain intact, the organisation can navigate change without
More news about: Leo International Group
Jan 13, 2026, 07:00 ET Identiv Recognized for Internet-of-Things Innovation in 10th Annual IoT Breakthrough Awards Program
immutable link between physical products and their digital twins. At the core are Identiv's tamper-detecting NFC inlays, powered by NXP®'s NTAG® 424 DNA TagTamper security chips, which detect interference and connect each bottle to its digital identity."For businesses and buyers, protecting authenticity
More news about: Identiv
Jan 13, 2026, 07:00 ET Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
non-small cell lung cancer.MRD testing helps clinicians track a patient's risk of cancer recurrence by detecting small traces of circulating tumor DNA (ctDNA) in a patient's bloodstream following treatment. This can signal molecular recurrence months before clinical relapse appears on traditional imaging
More news about: Labcorp
Jan 13, 2026, 03:00 ET n-Lorem und EspeRare kündigen europäische Zusammenarbeit zur Erweiterung des Zugangs zu individualisierten ASO-Therapien für seltene genetische Erkrankungen an
n-Lorem wurde gegründet, um diesen Patienten Hoffnung zu geben, indem individualisierte ASO-Therapien entwickelt werden – kurze Stränge modifizierter DNA, die präzise auf die Transkripte eines defekten Gens abzielen, um die Anomalie zu korrigieren. Diese experimentellen Therapien haben den Vorteil, schnell,
More news about: EspeRare Foundation